556 related articles for article (PubMed ID: 31114756)
1. A Metabolism Toolbox for CAR T Therapy.
Xu X; Gnanaprakasam JNR; Sherman J; Wang R
Front Oncol; 2019; 9():322. PubMed ID: 31114756
[TBL] [Abstract][Full Text] [Related]
2. Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.
Mangal JL; Handlos JL; Esrafili A; Inamdar S; Mcmillian S; Wankhede M; Gottardi R; Acharya AP
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807867
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
4. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies.
Krug A; Martinez-Turtos A; Verhoeyen E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008348
[TBL] [Abstract][Full Text] [Related]
5. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
6. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
7. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes.
Nanjireddy PM; Olejniczak SH; Buxbaum NP
Front Immunol; 2023; 14():1121565. PubMed ID: 36999013
[TBL] [Abstract][Full Text] [Related]
8. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and epigenetic orchestration of (CAR) T cell fate and function.
Akbari B; Hosseini Z; Shahabinejad P; Ghassemi S; Mirzaei HR; O'Connor RS
Cancer Lett; 2022 Dec; 550():215948. PubMed ID: 36209973
[TBL] [Abstract][Full Text] [Related]
11. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
Hawkins ER; D'Souza RR; Klampatsa A
Biologics; 2021; 15():95-105. PubMed ID: 33883875
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572932
[TBL] [Abstract][Full Text] [Related]
15. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
16. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
17. Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Irving M; Vuillefroy de Silly R; Scholten K; Dilek N; Coukos G
Front Immunol; 2017; 8():267. PubMed ID: 28421069
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.
Rad S M AH; Halpin JC; Mollaei M; Smith Bell SWJ; Hirankarn N; McLellan AD
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799768
[TBL] [Abstract][Full Text] [Related]
19. Target selection of CAR T cell therapy in accordance with the TME for solid tumors.
Liu B; Yan L; Zhou M
Am J Cancer Res; 2019; 9(2):228-241. PubMed ID: 30906625
[TBL] [Abstract][Full Text] [Related]
20. Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism.
Yang Q; Hao J; Chi M; Wang Y; Xin B; Huang J; Lu J; Li J; Sun X; Li C; Huo Y; Zhang J; Han Y; Guo C
Oncoimmunology; 2022; 11(1):2055703. PubMed ID: 35355679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]